Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ASND NASDAQ:IONS NASDAQ:RARE NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.83-0.5%$23.10$19.69▼$28.35$4.25B0.81.67 million shs1.27 million shsASNDAscendis Pharma A/S$252.66+0.3%$243.67$160.86▼$282.15$15.76B0.37707,698 shs308,314 shsIONSIonis Pharmaceuticals$55.87+3.4%$72.35$40.03▼$86.74$9.23B0.362.42 million shs3.83 million shsRAREUltragenyx Pharmaceutical$27.02-2.3%$27.38$18.29▼$39.89$2.66B0.312.24 million shs1.89 million shsUTHRUnited Therapeutics$529.53+0.5%$549.61$272.12▼$609.35$22.48B0.58485,472 shs241,115 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-1.85%-3.70%+12.99%+12.89%+10.59%ASNDAscendis Pharma A/S-1.28%-6.20%+10.50%+11.97%+52.19%IONSIonis Pharmaceuticals+1.16%-1.32%-28.83%-27.10%+28.75%RAREUltragenyx Pharmaceutical-3.39%-12.80%-4.75%+13.88%+4.58%UTHRUnited Therapeutics-1.63%-0.89%-2.09%-7.99%+76.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$24.83-0.5%$23.10$19.69▼$28.35$4.25B0.81.67 million shs1.27 million shsASNDAscendis Pharma A/S$252.66+0.3%$243.67$160.86▼$282.15$15.76B0.37707,698 shs308,314 shsIONSIonis Pharmaceuticals$55.87+3.4%$72.35$40.03▼$86.74$9.23B0.362.42 million shs3.83 million shsRAREUltragenyx Pharmaceutical$27.02-2.3%$27.38$18.29▼$39.89$2.66B0.312.24 million shs1.89 million shsUTHRUnited Therapeutics$529.53+0.5%$549.61$272.12▼$609.35$22.48B0.58485,472 shs241,115 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-1.85%-3.70%+12.99%+12.89%+10.59%ASNDAscendis Pharma A/S-1.28%-6.20%+10.50%+11.97%+52.19%IONSIonis Pharmaceuticals+1.16%-1.32%-28.83%-27.10%+28.75%RAREUltragenyx Pharmaceutical-3.39%-12.80%-4.75%+13.88%+4.58%UTHRUnited Therapeutics-1.63%-0.89%-2.09%-7.99%+76.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.67Moderate Buy$33.1733.57% UpsideASNDAscendis Pharma A/S 3.05Buy$296.7217.44% UpsideIONSIonis Pharmaceuticals 2.77Moderate Buy$95.9071.65% UpsideRAREUltragenyx Pharmaceutical 2.83Moderate Buy$58.41116.18% UpsideUTHRUnited Therapeutics 2.85Moderate Buy$648.3322.44% UpsideCurrent Analyst Ratings BreakdownLatest ACAD, ASND, RARE, IONS, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026ASNDAscendis Pharma A/S Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$256.00 ➝ $275.007/23/2026IONSIonis Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/23/2026UTHRUnited Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$685.00 ➝ $687.007/21/2026IONSIonis Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$106.00 ➝ $89.007/21/2026ACADACADIA Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $36.007/21/2026ACADACADIA Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$24.00 ➝ $25.007/17/2026IONSIonis Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026IONSIonis Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Peer Perform7/15/2026ASNDAscendis Pharma A/S Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C)7/13/2026IONSIonis Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$100.00 ➝ $85.007/10/2026IONSIonis Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$115.00 ➝ $100.00(Data available from 7/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B3.97$0.87 per share28.67$7.25 per share3.42ASNDAscendis Pharma A/S$814.57M19.35N/AN/A($2.97) per share-85.07IONSIonis Pharmaceuticals$1.06B8.73N/AN/A$3.02 per share18.50RAREUltragenyx Pharmaceutical$673M3.95N/AN/A($0.83) per share-32.55UTHRUnited Therapeutics$3.18B7.06$32.61 per share16.24$164.81 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2011.2928.8718.3234.30%9.61%7.07%8/4/2026 (Confirmed)ASNDAscendis Pharma A/S-$258M$8.6729.1420.80N/A57.87%N/A-8.37%8/6/2026 (Estimated)IONSIonis Pharmaceuticals-$381.39M-$2.07N/AN/AN/A-30.91%-58.65%-10.07%7/29/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-1,024.42%-45.78%8/4/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0919.5516.751.7940.62%19.24%17.25%8/5/2026 (Confirmed)Latest ACAD, ASND, RARE, IONS, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026ASNDAscendis Pharma A/S$1.29N/AN/AN/A$438.30 millionN/A8/4/2026Q2 2026ACADACADIA Pharmaceuticals$0.05N/AN/AN/A$295.51 millionN/A8/4/2026Q2 2026RAREUltragenyx Pharmaceutical-$1.2111N/AN/AN/A$183.08 millionN/A7/29/2026Q2 2026IONSIonis Pharmaceuticals-$1.0914N/AN/AN/A$189.06 millionN/A7/29/2026Q2 2026UTHRUnited Therapeutics$7.06N/AN/AN/A$805.01 millionN/A5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 million5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million4/29/2026Q1 2026IONSIonis Pharmaceuticals-$0.85-$0.56+$0.29-$0.56$195.57 million$246.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48ASNDAscendis Pharma A/S0.791.000.72IONSIonis Pharmaceuticals2.754.104.09RAREUltragenyx PharmaceuticalN/A2.021.85UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ASNDAscendis Pharma A/SN/AIONSIonis Pharmaceuticals93.86%RAREUltragenyx Pharmaceutical97.67%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%ASNDAscendis Pharma A/S40.00%IONSIonis Pharmaceuticals1.81%RAREUltragenyx Pharmaceutical5.20%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableIONSIonis Pharmaceuticals1,402165.26 million162.27 millionOptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.37 millionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableACAD, ASND, RARE, IONS, and UTHR HeadlinesRecent News About These CompaniesJPMorgan Chase & Co. Raises United Therapeutics (NASDAQ:UTHR) Price Target to $687.002 hours ago | marketbeat.comUnited Therapeutics Adds Victor Dzau to BoardJuly 23 at 7:51 AM | tipranks.comUnited Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of DirectorsJuly 23 at 6:30 AM | businesswire.comFirst Trust Advisors LP Has $160.45 Million Stock Position in United Therapeutics Corporation $UTHRJuly 23 at 4:00 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Dimensional Fund Advisors LPJuly 23 at 3:52 AM | marketbeat.comUnited Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 ReleaseJuly 22 at 11:01 AM | zacks.comUnited Therapeutics (UTHR) Projected to Release Quarterly Earnings on WednesdayJuly 22 at 6:10 AM | marketbeat.comSwiss National Bank Buys 2,320 Shares of United Therapeutics Corporation $UTHRJuly 22 at 5:03 AM | marketbeat.comMediolanum International Funds Ltd Decreases Position in United Therapeutics Corporation $UTHRJuly 22 at 5:03 AM | marketbeat.comAndra AP fonden Has $15.50 Million Stock Position in United Therapeutics Corporation $UTHRJuly 22 at 3:12 AM | marketbeat.com17,731 Shares in United Therapeutics Corporation $UTHR Purchased by SEB Asset Management ABJuly 21 at 5:28 AM | marketbeat.comCalifornia Public Employees Retirement System Grows Stock Holdings in United Therapeutics Corporation $UTHRJuly 21 at 3:51 AM | marketbeat.comHsbc Holdings PLC Decreases Stock Holdings in United Therapeutics Corporation $UTHRJuly 20 at 4:47 AM | marketbeat.comBank of New York Mellon Corp Trims Holdings in United Therapeutics Corporation $UTHRJuly 19, 2026 | marketbeat.comAurora Investment Counsel Cuts Stake in United Therapeutics Corporation $UTHRJuly 19, 2026 | marketbeat.comPrincipal Financial Group Inc. Acquires 3,534 Shares of United Therapeutics Corporation $UTHRJuly 18, 2026 | marketbeat.comDorsey Wright & Associates Acquires 5,839 Shares of United Therapeutics Corporation $UTHRJuly 18, 2026 | marketbeat.comAllspring Global Investments Holdings LLC Grows Stock Holdings in United Therapeutics Corporation $UTHRJuly 18, 2026 | marketbeat.comIllinois Municipal Retirement Fund Acquires 2,401 Shares of United Therapeutics Corporation $UTHRJuly 17, 2026 | marketbeat.comFinancial Comparison: IPSEN (OTCMKTS:IPSEY) & United Therapeutics (NASDAQ:UTHR)July 17, 2026 | americanbankingnews.comAware Super Pty Ltd as trustee of Aware Super Acquires Shares of 72,530 United Therapeutics Corporation $UTHRJuly 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026The Ugliest Stocks in the Market Just Got a Very Expensive Vote of ConfidenceBy Bridget Bennett | July 20, 2026IQM's Nasdaq Debut Could Change the Quantum Race for D-WaveBy Nathan Reiff | July 10, 2026Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBy Dan Schmidt | July 19, 20263 Rare-Earth ETFs That Help Investors Balance Exposure and RiskBy Chris Markoch | July 12, 2026ACAD, ASND, RARE, IONS, and UTHR Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$24.83 -0.13 (-0.52%) Closing price 04:00 PM EasternExtended Trading$24.83 0.00 (0.00%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Ascendis Pharma A/S NASDAQ:ASND$252.66 +0.73 (+0.29%) Closing price 04:00 PM EasternExtended Trading$251.94 -0.72 (-0.29%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Ionis Pharmaceuticals NASDAQ:IONS$55.87 +1.86 (+3.44%) Closing price 04:00 PM EasternExtended Trading$55.52 -0.35 (-0.62%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Ultragenyx Pharmaceutical NASDAQ:RARE$27.02 -0.63 (-2.28%) Closing price 04:00 PM EasternExtended Trading$27.04 +0.02 (+0.06%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.United Therapeutics NASDAQ:UTHR$529.53 +2.46 (+0.47%) Closing price 04:00 PM EasternExtended Trading$529.14 -0.39 (-0.07%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Alphabet Crushed Earnings, But One Number Spooked the Market Premium Retail’s Stress Test Is Separating Winners From Losers GE Vernova Just Sent a Mixed AI Signal to Investors Otis Took Another Guidance Cut—But the Story Isn't Over Philip Morris Trimmed Guidance, But Its Growth Story Looks Unshaken The 2026 Blueprint: 6 Stocks for a Brand New Portfolio Cementing the Sky: Why NVIDIA’s Bet on Nebius Matters Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
